Beneficial effect of Lactobacillus plantarum IS-10506 supplementation in adults with atopic dermatitis: a randomized controlled trial

Abstract

Introduction

Although the therapeutic effects of probiotics in atopic dermatitis (AD) are known, the limited findings in adults are inconsistent. Lactobacillus plantarum (LP) IS-10506 was found to improve AD symptoms due to its immunomodulatory effects.

Objective

To assess the Scoring Atopic Dermatitis Index (SCORAD), the serum immunoglobulin E (IgE), interleukin (IL)-4, interferon-gamma (IFN-γ), forkhead box P3 (Foxp3+), and IL-17 levels in adults with mild and moderate AD after LP IS-10506 supplementation.

Methods

A randomized double-blind placebo-controlled trial comparing the microencapsulated probiotic (2 × 10¹⁰ CFU/day) and placebo (skim milk-Avicel) was conducted at an outpatient clinic on 30 adults with mild and moderate AD. The patients were divided into 2 groups with 15 patients each: intervention and control.

Result

The SCORAD score was significantly lower in the probiotic than the placebo group on the 8th week. The IL-4 and IL-17 levels were significantly lower in the probiotic than the placebo group. The IFN-γ and Foxp3+ levels were significantly higher in the probiotic than the placebo group. However, the IgE levels remained significantly unchanged.

Conclusion

The administration of LP IS-10506 is effective for alleviating AD symptoms in adults owing to its immunomodulatory effects.

Keywords:

• Atopic dermatitis
• adult
• probiotic
• Lactobacillus plantarum

Acknowledgments

The authors would like to thank the Faculty of Engineering, Department of Food Technology, Bina Nusantara University for the generous support of the probiotics.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by Clinical Research Unit Dr. Soetomo General Teaching Hospital.